Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials
Menée à partir de données portant sur 838 patients pédiatriques atteints d'une leucémie myéloïde aiguë avec translocation t(8;21), cette étude internationale évalue l'association entre la présence d'anomalies génétiques (délétions chromosomiques, mutations des gènes cKIT et RAS, ...) et les résultats thérapeutiques (survie globale, survie sans événement et incidence cumulée de rechute)
In the article accompanying this editorial, Klein et al1 analyze results from 19 study groups assessing pediatric patients with acute myeloid leukemia (AML) during more than two decades in the largest pediatric t(8;21) AML cohort to date. Included are an analysis of the elements of intensive therapy that positively affect survival, as well as a description and characterization of the additional genomic changes in t(8;21) AML that may confer inferior survival rates. Patients with core binding factor (CBF) leukemia, including t(8;21) and inversion 16, have a better overall prognosis than that of other patients with non-CBF genomic alterations or normal cytogenetics. Nonetheless, event-free survival and relapse rates remain poor. In the International Berlin-Frankfurt-Münster (iBFM) data set, 27% of the patients with t(8;21) AML and a good prognosis died, mostly from progressive disease and despite aggressive therapy.
Journal of Clinical Oncology , éditorial en libre accès, 2015